Cellectis (ALCLS): Genome Engineering & CART Cells: At The Forefront Of Immuno-Oncology
9/2/2014 10:48:23 AM
NEW YORK--(BUSINESS WIRE)--Regulatory News:Cellectis (Alternext: ALCLS.PA), a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) will host a R&D/ Analyst Day on Thursday, September 11 at 7:30AM in New York City. Cellectis’ scientists will provide an overview of the Company's therapeutic innovations. The event will also feature presentations by key opinion leaders: Pr. Laurence Cooper, MD Anderson Cancer Center ; Dr. Jaume Pons Senior Vice President and CSO of Rinat, the biotech unit of Pfizer and Eric Falcand, Director, Alliance Management & US Licenses at Servier Laboratories.
Help employers find you! Check out all the jobs and post your resume.
comments powered by